Why These 24 Stocks Are Skyrocketing
One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.
Cidara Therapeutics Inc. (CDTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 1,092,796 | $29,374,356 | +56% | 0.39% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,092,796 | $29,374,356 | +56% | 0.99% |
| 3. | Vivo Capital Albert Cha And Frank Kung | 670,600 | $18,025,728 | 2.01% | |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 369,954 | $9,944,364 | +766% | 0.01% |
| 5. | Checkpoint Capital Sam Huang | 196,949 | $5,113,728 | +8% | 2.6% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.21 | 8,000 | Officer, Director | 24,580 | 2024-06-07 | Filing | |
| $0.97 | 10,000 | Officer | 294,179 | 2023-08-14 | Filing | |
| $0.96 | 50,000 | Officer, Director | 331,602 | 2023-08-08 | Filing | |
| $1.04 | 50,000 | Officer, Director | 281,602 | 2023-03-27 | Filing | |
| $1.59 | 50,000 | Officer, Director | 465,878 | 2021-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.96 | 1,664 | Officer | 14,674 | 2025-03-11 | Filing | |
| $21.96 | 1,773 | Officer | 16,215 | 2025-03-11 | Filing | |
| $11.64 | 924 | Officer | 23,067 | 2024-09-11 | Filing | |
| $11.64 | 909 | Officer | 17,788 | 2024-09-11 | Filing | |
| $0.67 | 21,029 | Officer | 258,681 | 2024-03-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,005,901 | $26,092,267 | 2.54% | |
| 2. | 765,723 | $20,582,634 | 1.41% | |
| 3. | 703,080 | $18,898,790 | 2.22% | |
| 4. | 217,504 | $5,846,508 | 0% | |
| 5. | 56,725 | $1,524,768 | 0.36% |
News See All
Should I Buy Cidara Therapeutics Inc (CDTX)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is Cidara Therapeutics Inc (CDTX) A Good Stock To Buy?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Is CDTX A Good Stock To Buy Now?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Here is What Hedge Funds Think About Cidara Therapeutics Inc (CDTX)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Fund and Insider Trading News: Jamie Dinan, Ray Dalio, Israel Englander, Air Products & Chemicals, Inc. (APD), Cidara Therapeutics Inc (CDTX), and More
Jamie Dinan, the founder of $17.6 billion York Capital and a co-owner of the NBA's Milwaukee Bucks, told attendees of Context Summits in Miami that Japan, a post-Brexit United Kingdom, and deleveraging...
Hedge Funds Bailed Out Of Cidara Therapeutics Inc (CDTX) Too Early
Does Cidara Therapeutics Inc (NASDAQ:CDTX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company.
Market Movers Today: Facebook, Inc. (FB), Geron Corporation (GERN), Heron Therapeutics Inc (HRTX), Micro Focus International PLC - ADR (MFGP), and More
Facebook Inc.'s stock tumbled Monday after the social media company accused a data analytics firm used by the Trump campaign of exploiting ill-gotten data belonging to unwitting Facebook users.
13G Filing: Broadfin Capital and Cidara Therapeutics Inc. (CDTX)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information...
Is The Cidara Therapeutics Inc (CDTX) Crash An Opportunity?
Cidara Therapeutics Inc (NASDAQ:CDTX) just announced data from a phase 2 study of one of its lead indications, and the outcome was unfavorable.